| 货号: S215355 |
| 产品全名: ATXN7 兔多抗 |
| 基因符号 SCA7; OPCA3; ADCAII |
| UNIPROT ID: O15265 (Gene Accession – NP_000324 ) |
| 背景: The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the ‘pure’ cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. This locus has been mapped to chromosome 3, and it has been determined that the diseased allele associated with spinocerebellar ataxia-7 contains 38-130 CAG repeats (near the N-terminus), compared to 7-17 in the normal allele. The encoded protein is a component of the SPT3/TAF9/GCN5 acetyltransferase (STAGA) and TBP-free TAF-containing (TFTC) chromatin remodeling complexes, and it thus plays a role in transcriptional regulation. Alternative splicing results in multiple transcript variants. |
| 抗原: Synthetic peptide of human ATXN7 |
| 经过测试的应用: ELISA, IHC |
| 推荐稀释比: IHC: 50-300; ELISA: 5000-10000 |
| 种属反应性: Rabbit |
| 克隆性： Rabbit Polyclonal |
| 亚型: Immunogen-specific rabbit IgG |
| 纯化: Antigen affinity purification |
| 种属反应性: Human, Mouse |
| 成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol |
| 研究领域: Neuroscience |
| 储存和运输: Store at -20°C. Avoid repeated freezing and thawing |
Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 215355(ATXN7 Antibody) at a dilution of 1/60(Cytoplasm). | 
In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 215355(Anti-ATXN7 Antibody) at dilution 1/60. | 
The image on the left is immunohistochemistry of paraffin-embedded Human lung cancer tissue using 215355(Anti-ATXN7 Antibody) at a dilution of 1/60. | 
In comparision with the IHC on the left, the same paraffin-embedded Human lung cancer tissue is first treated with synthetic peptide and then with D163249(Anti-ATXN7 Antibody) at dilution 1/60. |
|
